Laobaixing Pharmacy (SHG:603883) — Stock Price
Laobaixing Pharmacy (SHG:603883) is currently trading at CN¥12.74 CNY, up 2.82% today. Over the past 52 weeks, shares have ranged between CN¥10.96 and CN¥18.78. This page tracks Laobaixing Pharmacy's live share price on the SHG exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 603883 market cap.
Laobaixing Pharmacy (603883) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Laobaixing Pharmacy's daily closing share price and trading volume on the SHG exchange over the past year, giving a clear view of recent price momentum and liquidity.
Laobaixing Pharmacy Income Statement — Revenue, Profit & Earnings by Year
Laobaixing Pharmacy's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥22.24 Billion | CN¥22.36 Billion | CN¥22.44 Billion | CN¥20.18 Billion | CN¥15.70 Billion |
| Cost of Revenue | CN¥15.05 Billion | CN¥14.95 Billion | CN¥15.16 Billion | CN¥13.75 Billion | CN¥10.66 Billion |
| Gross Profit | CN¥7.18 Billion | CN¥7.41 Billion | CN¥7.28 Billion | CN¥6.42 Billion | CN¥5.04 Billion |
| Research & Development | CN¥51.07 Million | CN¥2.01 Million | CN¥2.51 Million | CN¥2.23 Million | — |
| SG&A | CN¥2.08 Billion | CN¥1.26 Billion | CN¥1.19 Billion | CN¥1.11 Billion | CN¥722.99 Million |
| Total Operating Expenses | CN¥21.09 Billion | CN¥6.50 Billion | CN¥5.88 Billion | CN¥5.22 Billion | CN¥4.08 Billion |
| Operating Income | CN¥1.14 Billion | CN¥913.57 Million | CN¥1.40 Billion | CN¥1.21 Billion | CN¥956.46 Million |
| EBITDA | — | CN¥1.34 Billion | CN¥1.66 Billion | CN¥1.53 Billion | CN¥1.16 Billion |
| EBIT | — | CN¥1.16 Billion | CN¥1.47 Billion | CN¥1.37 Billion | CN¥1.03 Billion |
| Interest Expense | CN¥130.27 Million | CN¥191.88 Million | CN¥185.60 Million | CN¥245.46 Million | CN¥203.87 Million |
| Income Before Tax | CN¥756.17 Million | CN¥915.97 Million | CN¥1.41 Billion | CN¥1.21 Billion | CN¥961.99 Million |
| Income Tax Expense | — | CN¥230.85 Million | CN¥284.27 Million | CN¥231.37 Million | CN¥175.26 Million |
| Net Income | CN¥381.85 Million | CN¥519.06 Million | CN¥929.02 Million | CN¥784.96 Million | CN¥669.24 Million |
Laobaixing Pharmacy Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Laobaixing Pharmacy's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥19.85 Billion | CN¥22.16 Billion | CN¥21.23 Billion | CN¥21.40 Billion | CN¥16.96 Billion |
| Total Current Assets | CN¥8.83 Billion | CN¥9.07 Billion | CN¥9.13 Billion | CN¥9.46 Billion | CN¥6.23 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | CN¥1.50 Million | CN¥3.00 Million | CN¥3.00 Million |
| Net Receivables | CN¥2.11 Billion | CN¥2.95 Billion | CN¥2.62 Billion | CN¥2.08 Billion | CN¥1.38 Billion |
| Inventory | CN¥3.65 Billion | CN¥3.57 Billion | CN¥4.15 Billion | CN¥3.95 Billion | CN¥2.73 Billion |
| Property, Plant & Equipment | — | — | — | — | CN¥4.67 Billion |
| Goodwill | CN¥5.61 Billion | CN¥5.76 Billion | CN¥5.84 Billion | CN¥5.49 Billion | CN¥3.70 Billion |
| Total Liabilities | CN¥12.85 Billion | CN¥14.99 Billion | CN¥13.94 Billion | CN¥14.30 Billion | CN¥12.18 Billion |
| Total Current Liabilities | CN¥10.16 Billion | CN¥10.92 Billion | CN¥11.16 Billion | CN¥10.85 Billion | CN¥8.61 Billion |
| Long-term Debt | CN¥1.43 Billion | CN¥1.40 Billion | CN¥1.38 Billion | CN¥1.58 Billion | CN¥875.14 Million |
| Net Debt | — | CN¥7.96 Billion | CN¥3.06 Billion | CN¥3.04 Billion | CN¥4.62 Billion |
| Total Stockholder Equity | CN¥6.54 Billion | CN¥6.58 Billion | CN¥6.70 Billion | CN¥6.53 Billion | CN¥4.36 Billion |
| Retained Earnings | CN¥3.72 Billion | CN¥3.55 Billion | CN¥3.69 Billion | CN¥3.10 Billion | CN¥2.54 Billion |
Laobaixing Pharmacy Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Laobaixing Pharmacy generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥3.14 Billion | CN¥2.03 Billion | CN¥2.73 Billion | CN¥2.31 Billion | CN¥2.30 Billion |
| Capital Expenditures | CN¥253.44 Million | CN¥507.50 Million | CN¥620.87 Million | CN¥308.44 Million | CN¥478.61 Million |
| Free Cash Flow | CN¥2.89 Billion | CN¥1.52 Billion | CN¥2.11 Billion | CN¥2.01 Billion | CN¥1.82 Billion |
| Investing Cash Flow | — | CN¥-721.54 Million | CN¥-761.26 Million | CN¥-1.46 Billion | CN¥-2.00 Billion |
| Financing Cash Flow | — | CN¥-1.25 Billion | CN¥-2.43 Billion | CN¥-142.62 Million | CN¥-413.21 Million |
| Dividends Paid | CN¥224.62 Million | CN¥637.37 Million | CN¥374.71 Million | CN¥223.98 Million | CN¥143.04 Million |
| Stock-Based Compensation | — | — | — | CN¥6.48 Million | CN¥32.14 Million |
| Depreciation | CN¥1.44 Billion | CN¥1.66 Billion | CN¥1.47 Billion | CN¥1.19 Billion | CN¥1.10 Billion |
| Change in Cash | CN¥157.11 Million | CN¥50.23 Million | CN¥-459.80 Million | CN¥716.74 Million | CN¥-117.72 Million |
Laobaixing Pharmacy Earnings History — EPS Actual vs. Analyst Estimates
Track Laobaixing Pharmacy's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 22, 2026 | -0.20 | 0.22 | -190.91% |
| Oct 28, 2025 | 0.17 | 0.19 | -10.53% |
| Aug 25, 2025 | 0.19 | 0.27 | -29.63% |
| Apr 29, 2025 | -0.15 | 0.24 | -162.50% |
| Oct 29, 2024 | 0.17 | 0.27 | -37.04% |
| Aug 29, 2024 | 0.11 | 0.32 | -65.63% |
| Apr 29, 2024 | 0.27 | 0.25 | +8.00% |
| Feb 27, 2024 | 0.37 | 0.36 | +2.78% |